Porvair Sciences has announced the addition of the novel Chromatrap chromatin immunoprecipitation (ChIP) assay range to its portfolio of products for epigenetics.
Developed in conjunction with Department of Life Sciences at University of Swansea, UK - Chromatrap® uses a solid phase porous polymer functionalized with protein A, allowing the chromatin capture to be more efficient than bead based methods.
The Chromatrap spin column approach offers significant advantages compared to methods based on sepharose or magnetic beads, which involve many steps of separation, pipetting and re-suspension.
Independent tests with Chromatrap demonstrate levels of DNA pull down up to 25 times higher than with traditional bead based procedures, excellent DNA enrichment with signal-to-noise ratios typically 2 to 3 times better than competing procedures and top performance even with samples as small as 50ng or as much as 3000ng chromatin per immunoprecipitation.
Steve Knight, Sales & Marketing Director for Porvair Sciences commented “Early adopters of ChromaTrap in pharmaceutical, healthcare and academic research have been delighted at the increased efficiency and precision they can routinely achieve compared to traditional bead-based ChIP technologies”.
He added “Not only are we adding an exciting new technology to our range of life science products but we are investing in the expertise of Dr. Amy Beynon who has a Ph.D in Neuroscience to support customers in this expanding area of research. As our Applications Development Manager, Dr Beynon will be best placed to support our worldwide Chromatrap users with optimizing their protocols to achieve the significant improvements in recoveries possible with the revolutionary Chromatrap technology".